Dimopoulos MA, et al. - In this phase 3, double-blind, placebo-controlled study (TOURMALINE-MM3), authors assessed 656 adults with a confirmed diagnosis of symptomatic multiple myeloma (as per International Myeloma Working Group criteria) to examine the safety and effectiveness of ixazomib as maintenance therapy after autologous stem cell transplantation, between July 31, 2014 and March 14, 2016. They observed a reduction of 28% in the risk of progression of disease or death with ixazomib than placebo. They noted no increase in incidence of second malignancies with ixazomib treatment. They suggested it as an additional choice for post-transplant maintenance therapy in newly diagnosed multiple myeloma cases as it prolonged progression-free survival.